Method for controlling angiogenesis in animals

A method for treating endometriosis comprising administering to a patient in need thereof a compound having the structure of formula (I) or a pharmaceutically acceptable salt thereof:

• wherein
• X is S or Se;
• W is O, S, or (R)(R), where each occurrence of R is independently H or C1-2alkyl;
• n is 0, 1 or an integer from 2 to 20;
• R1 and R2 are each independently C1-10alkyl;
• R3 is H, C1-10alkyl, or C0-6alkyl-COOR6;
• R3′ is H, amino, cyano, halogen, aryl, aralkyl, heteroaryl, heteroaralkyl, carboxyl, C1-10alkyl, C1-10alkenyl, or C1-10alkynyl;
• R4 is —OH, —H, —CH3, amino, —OC(O)C1-10aralkyl, —OC(O)C1-10alkyl, —OC(O)aryl, or a glutamine substituent;
• and
• R5 is —OH, cyano, C1-6alkoxy, amino, O—C1-10alkyl, O-aralkyl, —OC(O)C1-10aralkyl, —OC(O)C1-10alkyl, —OC(O)aryl, or a glycine substituent;
• and
• R6 is H or C1-10alkyl;
• or
• a compound having a structure of formula (III) or a pharmaceutically acceptable salt thereof
• wherein
• X is S or Se;
• W is O, S, or (R)(R), where each occurrence of R is independently H or a C1-2alkyl;
• Z is CH or N;
• R1 and R2 are independently C1-10alkyl, preferably R1 and R2 are independently selected from methyl, ethyl, propyl, and isopropyl;
• and
• R5 is —OH, cyano, C1-10alkoxy, amino, O-aralkyl, O-aralkyl, —OC(O)C1-10aralkyl, —OC(O)C1-10alkyl, —OC(O)aryl, or a glycine substituent;
• R6 is H or C1-10alkyl;
• R7 is selected from halogen, —OH, C0-6alkyl-COOR6, C1-6alkyl, C1-6alkoxy, amino, amido, cyano, and nitro;
• m is an integer from 0 to 4.